Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial

Gynecologic Oncology

Volumn 141, Issue 2, 2016, Pages 191-194

  Narod, Steven A ^a,b   Sopik, Victoria ^a,c   Giannakeas, Vasily ^a,b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; EFFECT SIZE; HAZARD RATIO; HUMAN; LATENT PERIOD; LIFE EXPECTANCY; LONG TERM SURVIVAL; MINIMAL RESIDUAL DISEASE; OVARIECTOMY; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; UNITED KINGDOM; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; FEMALE; MORTALITY; OVARY TUMOR; PROCEDURES;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; OVARIAN NEOPLASMS; UNITED KINGDOM;

EID: 84975709639     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.02.020     Document Type: Editorial

References (17)

1. National Centre for Health Statistics, National Vital Statistics Report. Deaths: Final data for 2013. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr64/nvsr64-02.pdf.
2. I. Jacobs, U. Menon, A. Ryan, and et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screenign (UKCTOCS): a randomized controlled trial Lancet 2015
3. R.J. Kurman, M.L. Carcangiu, C.S. Herrington, and R.H. Young WHO Classification of Tumors of Female Reproductive Organs fourth ed. 2014 International Agency for Research on Cancer Lyon 92 93
4. A. Finch, P. Shaw, B. Rosen, J. Murphy, S.A. Narod, and T.J. Colgan Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers Gynecol. Oncol. 100 2006 58 64
5. Surveillance, Epidemiology and End Results (SEER) Program research data (1973-2011), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, 2015 released April 2015, based on the November 2014 submission http://seer.cancer.gov. Accessed December 2015.
6. R. Sankaranarayanan, P.O. Esmy, R. Rajkumar, and et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomized trial Lancet 370 2007 398 406
7. D.D. Bowtell, S. Böhm, A.A. Ahmed, and et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Nat. Rev. Cancer 15 2015 668 679
8. S.J. Chang, M. Hodeib, J. Chang, and R.E. Bristow Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis Gynecol. Oncol. 130 2013 493 498
9. G.D. Aletti, B.S. Gostout, K.C. Podratz, and W.A. Cliby Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon Gynecol. Oncol. 100 2006 33 37
10. Gallagher J. Ovarian cancer: screening may cut deaths by a fifth. BBC News 2015 [online], http://www.bbc.com/news/health-35111443.
11. Knapton S. Screening could prevent one in five ovarian cancer deaths, study shows. The Telegraph 2015 [online], http://www.telegraph.co.uk/news/science/science-news/12056265/Screening-could-prevent-one-in-five-ovarian-cancer-deaths-study-shows.html.
12. V. Sopik, J. Iqbal, B. Rosen, and S.A. Narod Why have ovarian cancer mortality rates declined? Part II. Case-fatality Gynecol. Oncol. 138 2015 750 756
13. J. Kotsopolous, B. Rosen, I. Fan, and et al. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation Gynecol. Oncol. 2015 10.1016/j.ygyno.2015.11.009
14. U. Menon, A. Ryan, J. Kalsi, and et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening J. Clin. Oncol. 33 2015 2062 2071
15. V. Sopik, B. Rosen, and S.A. Narod Why have ovarian cancer mortality rates declined? Part III. Prospects for the future Gynecol. Oncol. 138 2015 757 761
16. D. Tewari, J.J. Java, and R. Salani Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 33 2015 1460 1466
17. S.A. Narod Can advanced-stage ovarian cancer be cured? Nat. Rev. Clin. Oncol. 2016 10.1038/nrclinonc.2015.224